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Protein conformation diseases, including polyglutamine (polyQ) diseases, result from
the accumulation and aggregation of misfolded proteins. Huntington’s disease (HD) is
one of nine diseases caused by an expanded polyQ repeat within the affected protein
and is hallmarked by intracellular inclusion bodies composed of aggregated N-terminal
huntingtin (Htt) fragments and other sequestered proteins. Fluorescence microscopy
and filter trap assay are conventional methods to study protein aggregates, but cannot
be used to analyze the presence and levels of post-translational modifications of
aggregated Htt such as ubiquitination. Ubiquitination of proteins can be a signal for
degradation and intracellular localization, but also affects protein activity and protein-
protein interactions. The function of ubiquitination relies on its mono- and polymeric
isoforms attached to protein substrates. Studying the ubiquitination pattern of aggregated
Htt fragments offers an important possibility to understand Htt degradation and
aggregation processes within the cell. For the identification of aggregated Htt and
its ubiquitinated species, solubilization of the cellular aggregates is mandatory. Here
we describe methods to identify post-translational modifications such as ubiquitination
of aggregated mutant Htt. This approach is specifically described for use with
mammalian cell culture and is suitable to study other disease-related proteins prone to
aggregate.
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INTRODUCTION
Various age-dependent neurodegenerative disorders, such
as Huntington’s disease (HD), Parkinson’s disease (PD) or
Alzheimer’s disease (AD), are hallmarked by aggregation of
misfolded proteins in neurons with age (Ross and Tabrizi, 2011;
Benilova et al., 2012; Irwin et al., 2013). HD is one of nine
polyglutamine (polyQ) diseases caused by an expansion of a
CAG trinucleotide repeat that encodes a polyQ tract in the
huntingtin (Htt) protein that triggers its aggregation (Yamada
et al., 2008). A neuropathological hallmark of HD is the presence
of intracellular inclusion bodies composed of mutant Htt
N-terminal fragments found in human postmortem brain,
animal models, and cell culture models (DiFiglia et al., 1997;
Gutekunst et al., 1999; Lunkes et al., 2002; Schilling et al., 2007;
Juenemann et al., 2011). The idea that intracellular inclusions
contain N-terminal fragments of Htt has been supported by
immunological studies, where inclusions of HD patients could
be stained by Htt antibodies against the N-terminal part of Htt
but not antibodies against the C-terminal part (Lunkes et al.,
2002). Moreover, pathological changes are accelerated in HD
mouse models overexpressing N-terminal fragments of mutant
Htt compared to those with full-length mutant Htt (Mangiarini
et al., 1996; Hodgson et al., 1999; Schilling et al., 1999; Wheeler
et al., 2000). Therefore, proteolytic processing of mutant Htt is
assumed to play a key role in the pathogenesis of HD.
The age-related decline in protein homeostasis challenges the
capacity of neurons to counteract the accumulation of misfolded
proteins, such as Htt fragments, and this may explain in part
the late onset of HD and other protein conformation diseases
(Balch et al., 2008). However, the role of inclusions in HD
has been challenged and inclusions have even been thought to
be protective (Arrasate et al., 2004; Arrasate and Finkbeiner,
2012). Interestingly, neuronal Htt aggregates found in human
postmortem brain material are positive for ubiquitin, indicating a
role of the ubiquitin-proteasome related protein quality control
system (DiFiglia et al., 1997; Gutekunst et al., 1999; Sieradzan
et al., 1999). Previous studies showed that wildtype and mutant
Htt are cleared by the proteasomal and autophagosomal pathways
(Wyttenbach et al., 2000; Waelter et al., 2001; Qin et al., 2003;
Thompson et al., 2009; Li et al., 2010; Juenemann et al., 2013).
Furthermore, Htt can be ubiquitinated at its N-terminal region,
suggesting specific ubiquitin-mediated degradation by cellular
clearance mechanism (Steffan et al., 2004; Juenemann et al., 2013;
Lu et al., 2013; Bhat et al., 2014).
Covalent attachment of ubiquitin to a lysine side chain of
a target protein is a multistep process. Different enzymatic
components are required for protein ubiquitination, including
ubiquitin-activating enzyme (E1), ubiquitin-conjugating
enzyme (E2), and ubiquitin-ligating enzyme (E3) (Hershko
and Ciechanover, 1998). Ubiquitin itself contains seven
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lysine residues that can be modified by successive rounds of
ubiquitination resulting in isopeptide-linked ubiquitin chains
of distinct topologies determining the cellular purpose of the
ubiquitinated substrate. Protein ubiquitination is important
for diverse intracellular processes such as degradation and
localization (Komander and Rape, 2012). Previous studies
have shown that Htt can be ubiquitinated via the action of
specific E3 ubiquitin ligases. Transient overexpression of the
co-chaperone and E3 ligase C-terminus of HSC70-interacting
protein (CHIP) increases the ubiquitination and clearance of
polyQ-expanded Htt and ataxin-3 in a cell culture model (Jana
et al., 2005). Overexpression of Ube3a in an HD knock-in mouse
model enhances mutant Htt degradation via the proteasomal
pathway resulting in reduced Htt aggregation (Bhat et al., 2014).
Furthermore, other E3 ubiquitin ligases, such as ERAD-associated
E3 ubiquitin-protein ligase (HRD1), TNF receptor-associated
factor 6 (TRAF6), and ubiquitin-like with PHD and ring
finger domains (UHRF-2), are supposed to ubiquitinate Htt
independent of the polyQ-length (Yang et al., 2007; Iwata et al.,
2009; Zucchelli et al., 2011).
Studying the intracellular ubiquitination pattern of soluble
and insoluble mutant N-terminal Htt fragments offers a
valuable insight into Htt aggregation, and reveals whether Htt
is properly ubiquitinated for proteasomal or autophagosomal
degradation.
To study the composition of Htt species in aggregates
solubilization thereof is mandatory. Hazeki et al. showed that
Htt aggregates occuring in transfected COS cells overexpressing
mutant Htt-exon1 can be solubilized by pure formic acid
into monomeric forms (Hazeki et al., 2000). High molecular
weight complexes of mutant Htt dissociate in concentrated
formic acid and HCl, whereas 8M Urea, 6M Guanidine/HCl,
1N NaOH and pure acedic acid showed low potential to
interfere with Htt complex stability. In addition, Iuchi et al.
showed that inclusions in PC12 cells formed by polyQ-
stretches of the mutant androgen receptor are dissolved to
monomers by the use of concentrated formic acid (Iuchi
et al., 2003). Dissociation of inclusion bodies in T-hd122
cells expressing truncated mutant Htt revealed ubiquitination
of the Htt proteolytic cleavage fragment cp-A (Lunkes et al.,
2002).
Here we describe protocols for solubilization of Htt
aggregates, based on sodium dodecyl sulfate (SDS) and formic
acid treatment, which allow to identify post-translational
modifications such as ubiquitination. The described methods
for solubilization of intracellular inclusion bodies composed
of mutant Htt N-terminal fragments can be potentially




The Htt-exon1-97Q construct was generated by replacing
the C-terminal green fluorescent protein (GFP) sequence
of Htt-exon1-97Q-GFP (kindly provided by R. Kopito,
Stanford University, USA) for a stop codon and the Htt-
exon1-97Q-H4 construct was generated by cloning the
Htt-exon1-97Q sequence with a 5’ XhoI and 3’ BamHI site
into a vector encoding a C-terminal H4-tag (His-HA-HA-
His, kindly provided by J. Steffan, University of California,
USA). The reporter construct Htt-exon1-25Q-GFP was
kindly provided by R. Kopito and the ubiquitin constructs
HA-Ub-wt and HA-Ub-K0 were a kind gift from N. Zelcer
(Academic Medical Center, University of Amsterdam, The
Netherlands).
CELL CULTURE AND TRANSFECTION
Neuro-2a cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) (Invitrogen) supplemented with 10% fetal
calf serum, 1 mM glutamine, 100 U/mL penicillin, and
100 µg/mL streptomycin in a humidified incubator with
5% atmospheric CO2. Neuro-2a cells were seeded in 6-well
plates and transfected with polyethylenimine according to the
manufacturer’s instructions (Polysciences Europe).
WESTERN BLOT ANALYSIS OF TRITON X-100 SOLUBLE PROTEINS
Neuro-2a cells were harvested in lysis buffer (50 mM Tris/HCl
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100,
20 mM NEM, supplemented with complete mini protease
inhibitor cocktail (Roche)) 24 h after transfection. Total cell
lysate was boiled for 10 min at 99◦C with 1x laemmli sample
loading buffer (350 mM Tris/HCl pH 6.8, 10% SDS, 30%
glycerol, 6% β-mercaptoethanol, bromphenol blue), fractionated
on a 12% SDS-gel by SDS-PAGE gel electrophoresis and
transferred to a polyvinylidene fluoride (PVDF) membrane
(0.45 µm pore size, Schleicher and Schuell). Western blot
membranes were blocked with 5% milk, incubated with
primary antibodies anti-Htt 1C2 (1:1000, Millipore, MAB1574),
anti-Htt N18 (1:1000, Enzo, BML-PW0595-0100), anti-HA
(1:1000, Sigma- Aldrich, H3663), anti-β-actin (1:1000, Santa
Cruz, SC-130656), and anti-ubiquitin (1:100, Sigma-Aldrich,
U5379), and subsequently incubated with secondary antibodies
IRDye 680 or IRDye 800 (1:10,000; LI-COR Biosciences).
Infrared signal was detected using the Odyssey imaging system
(Licor).
FILTER TRAP ASSAY
For analysis of Triton X-100-insoluble aggregates, filter
trap assay was performed with the pellet obtained after
centrifugation of the Triton X-100 cell lysate (15 min at
14,000 rpm at 4◦C). Pellet with aggregates was resuspended
in benzonase buffer (1 mM MgCl2, 50 mM Tris/HCl pH
8.0) and incubated for 1 h at 37◦C with 125 U Benzonase
(Merck). Reaction was stopped with 2x termination buffer
(40 mM EDTA, 4% SDS, 100 mM DTT). Samples with a
protein concentration of 50 µg were diluted in 2% SDS
buffer and filtered through a 0.2 µm pore size cellulose
acetate membrane (Schleicher and Schuell), pre-equilibrated
in 2% SDS wash buffer (2% SDS, 150 mM NaCl, 10 mM
Tris/HCl pH 8.0) and spotted on the membrane in doublets.
Filters were washed twice with 0.1% SDS buffer (0.1%
SDS, 150 mM NaCl, 10 mM Tris pH 8.0) and blocked
with 5% milk for further treatment similar to western blot
membranes.
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FLUORESCENCE MICROSCOPY
Neuro-2a cells were seeded on coverslips in a 6-well plate and
transfected with the indicated DNA constructs 24 h prior to
imaging. Transfected cells were fixed with 4% paraformaldehyde
(PFA) and images were obtained using a confocal microscope
equipped with an Ar/Kr laser and a 63x objective (Leica TCS SP8).
SDS-SOLUBLE/INSOLUBLE FRACTIONATION FOR ANALYSIS OF
POST-TRANSLATIONAL MODIFICATIONS
Procedure
1. Cells grown in a 6-well plate were washed with 1 mL ice cold 1x
PBS and harvested in 0.5 mL ice cold 1x PBS with a cell scraper.
2. The cell suspension was transferred to a 1.5 mL tube and
centrifuged for 5 min (2000 rpm, 4◦C).
3. After discarding the supernatant, cells were lysed by adding
0.1 ml 1x TEX buffer directly on top of the cell pellet without
pipetting up and down (cell pellet should get loose from the
tube wall) followed by immediate high speed vortexing for
5–10 s.
4. Sample was sonicated with a benchtop Ultrasonic
Disintegrator (Soniprep150, Sanyo) using a 10 s pulse
until the sample got liquid and was not slurry anymore.
5. In addition, the DNA was sheared by passing the sample
solution 6 times through a 21 Gauge needle.
6. The proteins were reduced by adding 5 µl 1 M DTT (fresh) to
the sample and subsequently boiled for 10 min at 99◦C in a
thermoblock while shaking at 1000 rpm.
7. Afterwards the sample was immediately centrifuged for at least
60 min (14,000 rpm, RT).
8. Maximal four samples at once were taken out of the centrifuge
and the remaining samples were continuously centrifuged
until further use.
9. The supernatant (SDS-soluble fraction) was carefully
transferred into a new tube containing 5 µl concentrated
bromphenol blue solution (soluble fraction) carefully
avoiding to touch the SDS-insoluble pellet.
!Caution: The SDS-insoluble pellet is invisible and detaches
very easily from the tube wall.
10. For solubilization of the SDS-insoluble aggregates, 10 µl 100%
formic acid was added to the pellet and pipetted several times
up and down.
11. The suspension was incubated for 40 min at 37◦C while
shaking at 1000 rpm in a thermoblock.
12. Then the formic acid was evaporated overnight at 30◦C using
a Speedvac system (Eppendorf).
13. The remaining protein pellet was solved in 50 µl 1x TEX blue
buffer by pipetting up and down (SDS-insoluble fraction).
!Caution: If the formic acid is not fully evaporated after
step 12 the sample will be still acidic and the bromphenol
blue indicator will switch color from blue to green/yellow. In
this case, the sample can be neutralized by adding 5 µl 1 M
Tris/HCl pH 8.0.
14. The sample was boiled for 10 min at 99◦C while shaking at
1000 rpm.
15. To visualize formic acid-dissolved aggregates by western blot
analysis 25–50 µl of the SDS-insoluble fraction was loaded on
a 12% SDS-PAGE gel.
!Caution: To compare several SDS-insoluble fractions,
equivalent volumes have to be loaded.
16. Not immediately used sample fractions were stored at 4◦C.
Buffers
1x PBS: 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2PO4,
1.4 mM KH2PO4, adjust to pH 7.4
1x TEX buffer: 70 mM Tris/HCl pH 6.8, 1.5% SDS,
20% glycerol (store at RT)
1x TEX buffer blue: 70 mM Tris/HCl pH 6.8, 1.5% SDS,
20% glycerol, tip of a spatula of
bromphenol blue (store at RT)
Concentrated bromphenol spatula-tip of bromphenol blue
blue solution: solved in water (store at RT)
RESULTS AND DISCUSSION
Htt contains three lysine residues (K6, K9, K15) at the N17
region for putative ubiquitination (Figure 1A). Previous
work from Steffan et al. has shown that mutation of
these three lysines to arginines obviates ubiquitination and
SUMOylation of soluble Htt-exon1 in cell culture (Steffan
et al., 2004). An AQUA-MS approach revealed that less than
1% of soluble N-terminal Htt expressed in HEK 293 cells
is ubiquitinated without considering inhibition of cellular
degradation pathways (Hipp et al., 2012). Immunoprecipitation
and mass spectrometry analysis are appropriate methods to
identify specific soluble protein-ubiquitin conjugates. However,
once misfolded proteins start to aggregate and interacting
partners are co-sequestered, this represents a challenge in
terms of isolation and detection of specific protein-ubiquitin
conjugates.
In the last two decades, various methods have been established
to detect and analyze aggregates of misfolded proteins related
to neurodegeneration. Htt with an expanded polyQ-stretch
is prone to misfold, triggering its aggregation, a property
tightly associated with its neurotoxicity (Takahashi et al.,
2010; Miller et al., 2011). Htt can be found in vitro and in
vivo in a monomeric or aggregated state, and they are both
detectable with different methods, including microscopic
techniques, fluorescence-activated cell sorting (FACS) analysis
or biochemical approaches. Until now, these methods are
not applicable for analyzing post-translational modified
Htt species trapped in aggregates, especially with respect to
distinguishing between Htt-ubiquitin conjugates and Htt that
is non-covalently associated with monoubiquitin, polyubiquitin
conjugates or other co-sequestered polyubiquitinated
proteins.
To investigate the connection between ubiquitination and
intracellular aggregation of Htt, cells overexpressing Htt-
exon1-97Q and as a control a mutant form lacking three
N-terminal lysine residues (3xR mutant) necessary for Htt
ubiquitination were analyzed by fluorescence microscopy, western
blot analysis and filter trap assay. To study whether aggregation
of Htt depends on its ubiquitination Neuro-2a cells were
co-transfected with either Htt-exon1-97Q or its 3xR mutant
variant and the aggregation reporter Htt-exon1-25Q-GFP,
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FIGURE 1 | Conventional methods to study Htt protein aggregates.
(A) Scheme of the Htt-exon1 protein fragment. N-terminal region (aa 1-17)
of wildtype Htt-exon1 with three lysine residues (K6, K9, K15) compared
to the Htt mutant (3xR) containing three arginine residues (R6, R9, R15).
(B) Aggregates of wildtype and 3xR mutant Htt-exon1. Transient
co-transfection of Neuro-2a cells with the aggregation reporter
Htt-exon1-25Q-GFP and wildtype or 3xR mutant Htt-exon1-97Q-H4
constructs. After 24 h cells were fixed and aggregates of Htt-exon1
co-sequestering the aggregation reporter Htt-exon1-25Q-GFP were
detected by fluorescence of GFP. The nucleus was stained by
4’,6-diamidino-2-phenylindole (DAPI). Scale bar: 10 µm. (C) Western blot
analysis and (D) filter trap assay (in doublets) of cell lysates from Neuro-2a
cells transient transfected for 24 h with wildtype and 3xR mutant
Htt-exon1-97Q-H4 constructs. Triton X-100-soluble Htt-exon1 proteins and
insoluble Htt aggregates (asterisk) in the stacking gel were detected on
immunoblots with HA antibody. β-actin was used as loading control. Filter
trap assay was performed using an antibody against the HA-tag of Htt and
an antibody against ubiquitin (Ub) recognizing ubiquitinated proteins.
respectively, and analyzed using confocal fluorescence microscopy
(Figure 1B). The aggregation reporter Htt-exon1-25Q-GFP
shows a diffuse cellular staining unless sequestered into
aggregates (Juenemann et al., 2013). Both wildtype and 3xR
mutant Htt-exon1-97Q form inclusion bodies within 24 h
after transfection as detected with the GFP-tagged Htt-
exon1-25Q reporter protein that becomes sequestered into
the mutant Htt-exon1-Q97 aggregates, indicating that Htt
aggregation is independent of its ubiquitination. To evaluate
whether Htt aggregates are detectable by western blot Triton
X-100 soluble fractions of cells transfected with Htt-exon1-
97Q-H4 or 3xR mutant Htt-exon1-97Q-H4 were separated
by SDS-PAGE. Both Triton X-100 insoluble Htt aggregates
in the stacking gel (asterisk) and the soluble Htt-exon1
monomer were recognized by using a mouse monoclonal HA
antibody (Figure 1C). The Triton X-100 insoluble aggregates
of the same transfected Neuro-2a cells were applied to
a filter trap assay. The filter trap membrane was stained
against Htt-exon1-97Q-H4 and ubiquitin using an HA and a
ubiquitin antibody (Figure 1D). Both wildtype and 3xR mutant
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FIGURE 2 | A stepwise protocol of SDS-soluble and SDS-insoluble cell fractionation.
Htt-exon1-97Q aggregates showed a positive ubiquitin staining,
which could either mean that the three Htt N-terminal lysine
residues are not essential for ubiquitination, there is aggregate
association with ubiquitin or other ubiquitinated proteins are
co-sequestered.
Together, this indicates that with microscopy, immunoblot
and filter trap assay there is no discrimination between
ubiquitin covalently bound to aggregated Htt-exon1 and non-
covalently associated monoubiquitin, polyubiquitin conjugates or
sequestered polyubiquitinated proteins. To identify ubiquitinated
Htt species besides monomeric Htt within aggregates an
adequate solubilization is required that is capable of destroying
the strong non-covalent interactions between the aggregated
proteins.
Here we provide a protocol suitable for subsequent
biochemical protein analysis of aggregates, consisting of mutant
Htt, by solubilizing them with 100% formic acid (Figure 2).
Formic acid disrupts protein interactions such as hydrogen
bonds. Previous work indicated that aggregation of Htt results
from the formation of hydrogen bonds between polyQ stretches
forming β-sheet structures (Perutz et al., 1994). Hazeki et al.
showed that only formic acid and HCl but not acedic acid, Urea,
Guanidine/HCl or NaOH dissociate higher molecular weight
complexes of mutant Htt (Hazeki et al., 2000).
In order to solubilize SDS-insoluble protein pellets containing
aggregated Htt from Neuro-2a cells transfected with the
constructs encoding Htt-exon1-97Q and its 3xR Htt mutant
variant, pellets were treated with 100% formic acid followed by
SDS-PAGE and immunoblot analysis. The formic acid treated
SDS-insoluble fraction showed the presence of monomeric
Htt-exon1-97Q at around 45 kDa (arrow) and at higher
molecular weight post-translational modified species of Htt-
exon1-97Q in form of distinct bands (Figure 3A). Htt was
stained by the Htt-specific antibodies 1C2 against the polyQ
tract and N18 against the N-terminal region. With the 3xR Htt
mutant variant the higher molecular Htt bands disappeared,
indicating that the post-translational modification of Htt is
dependent on the N-terminal lysine residues. The size difference
between the distinct bands suggests a ubiquitination of Htt.
The observation that the aggregated 3xR Htt mutant does not
show this high molecular weight bands indicates that the Htt
N-terminal lysine residues are the ubiquitination sides and
not, as described as more rare forms of ubiquitination, serine,
threonine and cysteine residues or the N-terminal α-amino
group ubiquitination in a linear fashion (McDowell and Philpott,
2013).
To confirm that the higher molecular weight protein ladder
of formic acid-dissolved HA-tagged Htt-exon1-97Q indeed
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FIGURE 3 | Detection of aggregated Htt and its ubiquitinated species.
(A) SDS-insoluble fraction of Neuro-2a cell lysate after transient transfection
of cells with wildtype or 3xR mutant Htt-exon1-97Q constructs. Formic
acid-dissolved aggregates of Htt were detected on western blot by the
Htt-specific antibodies 1C2 and N18. Formic acid soluble Htt-exon1 monomer
(arrow) and a higher wildtype Htt-specific protein ladder, which is not
detectable with 3xR mutant Htt, are shown. Remaining non-dissolved Htt
aggregates were trapped in the stacking gel and recognized by the N18
antibody only. (B) Western blot analysis of the SDS-insoluble fraction of
Neuro-2a cells transiently transfected with Htt-exon1-97Q-H4. In addition to
the monomeric Htt-exon1-97Q-H4 protein a ubiquitin-positive Htt protein
ladder (asterisks) is shown by the HA and ubiquitin (Ub) antibody, respectively.
(C) Western blot analysis of the SDS-insoluble fraction of Neuro-2a cells
transiently co-transfected with Htt-exon1-97Q and the ubiquitin constructs
HA-Ub-wt and its lysine-dead mutant HA-Ub-K0, respectively. In addition to
the monomeric Htt-exon1-97Q protein a ubiquitin-positive Htt protein ladder is
shown by the 1C2 and Ub antibody, respectively. Lysine residue-dependent
integration of HA-Ub-wt into the Htt-exon1 polyubiquitination chains is shown
by an upward shift of the ubiquitin-modified Htt bands at the size of the
ubiquitin N-terminal HA-tag (asterisks).
represents polyubiquitinated Htt, membranes were stained in
parallel with an HA antibody and a ubiquitin antibody. Both
antibodies detect the same protein bands indicating that the
specific bands are ubiquitinated species of Htt-exon1 (asterisks)
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(Figure 3B). Worth mentioning is the difference between the used
antibodies regarding the recognition of formic acid-nondissolved
aggregates in the SDS stacking gel. The Htt specific N-terminal
polyclonal N18 antibody and the HA antibody against the C-
terminal HA-tag of the Htt protein compared to the Htt-specific
monoclonal 1C2 antibody and the ubiquitin antibody are capable
of detecting higher molecular Htt aggregates in the SDS stacking
gel. The solubilization of Htt aggregates by pure formic acid
is incomplete, since aggregates are still detectable by certain
antibodies in the stacking gel. This might be a consequence
of high Htt accumulation due to overexpression and part of
the aggregates are not solved in time, or of the potentially
formic acid-resistant aggregated Htt species. Previous studies
suggested that aggregated Htt is crosslinked by covalent bonds
such as those formed by transglutaminase (Kahlem et al., 1996;
Cooper et al., 2002; Iuchi et al., 2003; Zainelli et al., 2003,
2004).
To validate Htt ubiquitination in cellular aggregates, SDS-
insoluble Htt from Neuro-2a cells co-transfected with Htt-exon1-
97Q and either HA-tagged Ub-wt or Ub-K0, where all the lysine
residues are exchanged to an arginine to prevent ubiquitination,
was analyzed. Incorporation of HA-Ub into the Htt polyubiquitin
chain is indicated by shifts of each Htt-Ub bands upwards
in the size of one (about 1 kDa, asterisks) or more HA-tags
creating indistinct protein bands as detected by the 1C2 antibody
(Figure 3C). Co-staining with the HA antibody confirms covalent
binding of the overexpressed HA-Ub-wt to the Htt-exon1 protein
and its ubiquitinated species (asterisks) showing that Htt gets
post-translational modified by ubiquitin. However, co-expression
of HA-Ub-K0 reveals no incorporation of ubiquitin lacking lysine
residues.
Here we provide a protocol for the solubilization of aggregated
Htt proteins using formic acid to detect ubiquitinated species
of overexpressed mutant Htt-exon1. Whether this method
is sensitive enough to detect ubiquitination of endogenous
expressed Htt depends on the quantity of aggregated Htt and
the rate of Htt ubiquitination/deubiquitination. The presented
methods might be transferrable to study other neurodegenerative
diseases besides HD that are hallmarked by misfolded proteins
prone to aggregate. In addition, the protocol may be applied
to analyze other post-translational modifications of misfolded
proteins in SDS-insoluble aggregates, such as SUMOylation,
phosphorylation or acetylation.
While studying the role of ubiquitination of a specific
misfolded protein within the cell it is important to distinguish
between the analyzed misfolded protein covalently binding
ubiquitin and ubiquitin only associated with the aggregate such
as co-sequestered polyubiquitinated proteins.
Further research and the identification of the ubiquitin linkage
pattern of soluble and insoluble Htt dependent on the length
of the polyQ stretch or cellular localization is important to
understand the fate of this protein within the cell. Unraveling the
disease-related alterations of Htt post-translational modifications
will certainly fill a crucial gap between the current knowledge of
Htt fragment generation and aggregation on the one side, and
regulation of potent degradation machineries on the other side
that are capable of obviating toxicity of Htt species within the cell.
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